Michael Recht, MD, PhD, MBA
he/him/his
Professor of Clinical Pediatrics (Hematology/Oncology)Cards
About
Research
Publications
2025
Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors
Buckner T, Kessler C, Castaman G, Hermans C, Jiménez‐Yuste V, Mahlangu J, Miesbach W, Oldenburg J, Recht M, Valentino L, Wheeler A, Pipe S. Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors. Haemophilia 2025, e70077. PMID: 40534395, DOI: 10.1111/hae.70077.Peer-Reviewed Original ResearchInitial dosing regimensVisual analogue scaleBleeding episodesScore reductionReceiver operating characteristicEptacog betaPain reductionPain levelsTreatment responseVisual analogue scale score reductionBeta treatmentTreatment outcomesMean VAS scorePain score reductionTreat bleeding episodesVAS score reductionBaseline pain levelsAssess treatment responseEvaluate treatment responseEvaluate pain reductionControl of bleedingPredicting treatment outcomePost hoc studyPatient-reported outcomesBleed resolutionInhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US Cohort Study
Thornburg C, van den Berg H, Chandler M, Malec L, Manuel M, O’Neill C, Recht M, Taggart E, Carpenter S, group A, Knoll C, Malec L, Wang M, Guerrera M, Tarango C, Sidonio R, Rodriguez N, Friedman K, Shapiro A, Yaish H, Carpenter S, Janbain M, Grabowski E, Pruthi R, Haley K, Thornburg C, Ahuja S, Simpson M, Reiss U, Lucas T, Balasa V, Wheeler A. Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US Cohort Study. Blood Vessels Thrombosis & Hemostasis 2025, 100082. DOI: 10.1016/j.bvth.2025.100082.Peer-Reviewed Original ResearchClotting factor concentratesSevere hemophilia AHemophilia AInhibitor developmentExposure daysCohort studyAssociated with inhibitor developmentLow-titer inhibitorsReduce inhibitor developmentHigh-titer inhibitorsCox proportional hazards modelsEvaluate risk factorsClinically significant inhibitorUS cohort studyProportional hazards modelCongenital hemophiliaUntreated patientsSevere HAClinical characteristicsPrevent bleedingNeutralizing antibodiesModerate haemophiliaNonsense variantFactor concentrationsRisk factorsCompletion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Monahan P, Le Quellec S, Pipe S. Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. Blood Advances 2025 PMID: 40188458, DOI: 10.1182/bloodadvances.2024015291.Peer-Reviewed Original ResearchAdeno-associated virus serotype 5Etranacogene dezaparvovecHemophilia BRecombinant adeno-associated virus serotype 5FIX inhibitor developmentLiver-specific promoterPost-administrationSelf-administered infusionsSevere hemophilia BMulti-center trialYears post-administrationBleeding episodesOpen-labelSingle-doseSecondary endpointsIntravenous doseSingle-armGene therapyThrombotic complicationsYears post-treatmentSafety profileClinically significant elevationsAdverse eventsBleeding frequencyNeutralizing antibodiesCorticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance
Konkle B, Peyvandi F, Foster G, Hermans C, La Mura V, Leavitt A, Lillicrap D, Mahlangu J, Ozelo M, Pipe S, Recht M, Srivastava A, Young G, Miesbach W. Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. Journal Of Thrombosis And Haemostasis 2025, 23: 2086-2094. PMID: 40090623, DOI: 10.1016/j.jtha.2025.02.042.Peer-Reviewed Original ResearchSevere hemophilia AValoctocogene roxaparvovecFactor VIIIGene therapyHemophilia AMarkers of hepatocyte injuryFactor VIII activity levelsCourse of corticosteroidsFactor VIII levelsElevated alanine transaminaseReduced FVIII levelsClinical practice guidanceFVIII levelsCorticosteroid useAdverse eventsClinical dataClinical trialsCorticosteroidsHepatocyte injuryAlanine transaminaseTherapyPatientsActivity levelsExpert opinionAdultsAmerican Thrombosis and Hemostasis Network: National Bleeding Disorders Foundation Data Commons: Better Together
Chrisentery‐Singleton T, Gattone P, Gerber C, Mills K, Miles M, Rotellini D, Santaella M, Valentino L, Watson C, Recht M. American Thrombosis and Hemostasis Network: National Bleeding Disorders Foundation Data Commons: Better Together. Haemophilia 2025, 31: 589-593. PMID: 39982786, DOI: 10.1111/hae.70011.Peer-Reviewed Original ResearchContemporary approaches to treat people with hemophilia: what’s new and what’s not?
Valentino L, Santaella M, Carlson S, Recht M. Contemporary approaches to treat people with hemophilia: what’s new and what’s not? Research And Practice In Thrombosis And Haemostasis 2025, 9: 102696. PMID: 40084158, PMCID: PMC11905833, DOI: 10.1016/j.rpth.2025.102696.Peer-Reviewed Original ResearchComprehensive interdisciplinary careCare of peopleMiddle-income countriesBispecific monoclonal antibodyStandard of careHealth equityNonfactor productsFactor replacementHemophilia AJoint bleedsGenetic therapiesHemophiliaNormal hemostasisMonoclonal antibodiesAnticoagulant mechanismsTargeted inhibitorsUnaffected peersHaemophilia careBleedingNarrative reviewTreatmentTreatment of peopleAverage life expectancyInterdisciplinary careDiagnosis
2024
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors
Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Jiménez‐Yuste V, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery‐Singleton T, Bonzo D, Mitchell I, Wilkinson T, Young G. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia 2024, 31: 78-86. PMID: 39676340, PMCID: PMC11780187, DOI: 10.1111/hae.15109.Peer-Reviewed Original ResearchConceptsIncidence of rebleedingLow incidence of rebleedingEptacog betaBleeding episodesHemophilia ALow incidenceInitial dosing strategyControl of bleedingIntention-to-treat analysisReview treatment outcomesRecombinant FVIIaDosing strategiesRebleeding incidenceAdolescent patientsBleeding controlBleeding treatmentRebleedingRebleedPatient populationTreatment outcomesTreatment dataHemophiliaBleedingPerioperative carePatientsContrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
Skinner M, Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell N, Crato M, Dargaud Y, d'Oiron R, Dunn A, Escobar M, Escuriola‐Ettingshausen C, Gouider E, Harroche A, Hermans C, Jimenez‐Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce G, Ramos G, Recht M, Romero‐Lux O, Rotellini D, Santoro R, Singleton T, Srivastava A, Susen S, Talks K, Tran H, Valentino L, Windyga J, Yang R, Mancuso M, also on behalf of AICE A. Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease. Haemophilia 2024 PMID: 39648854, DOI: 10.1111/hae.15136.Peer-Reviewed Original ResearchClinical practice guidelinesGRADE methodologyGuideline development processExpert healthcare professionalsRandomized controlled trialsPatient participationIncorporation of outcomesHealthcare professionalsGuideline developmentVon Willebrand diseaseGuideline recommendationsEvidence basePractice guidelinesStakeholder inputManagement of hemophiliaHaemophilia careControlled trialsISTH guidelinesCongenital hemophiliaContent expertiseWillebrand diseaseRare diseaseHemophiliaGuidelinesHaemophilia managementInternational Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell N, Crato M, Dargaud Y, d'Oiron R, Dunn A, Escobar M, Ettingshausen C, Fischer K, Gouider E, Harroche A, Hermans C, Jimenez‐Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Mancuso M, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce G, Ramos G, Recht M, Romero‐Lux O, Rotellini D, Santoro R, Singleton T, Skinner M, Srivastava A, Susen S, Talks K, Tran H, Valentino L, Windyga J, Yang R, also on behalf of AICE A. International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal. Haemophilia 2024 PMID: 39642092, DOI: 10.1111/hae.15135.Peer-Reviewed Original ResearchClinical practice guidelinesTreatment goalsGRADE methodologyPractice guidelinesClinical practiceEvidence-based clinical practice guidelinesTreatment of hemophiliaWell-designed observational studiesRandomized controlled trialsPatient-relevant outcomesOptimal patient careRare diseaseTherapeutic benefitObservational studyControlled trialsHigh-quality treatmentHealthcare professionalsPatient preferencesPatient careCritical appraisalPatient communityHaemophilia careHemophiliaTreatmentPatientsEffectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset
Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal Of Haematology 2024, 114: 448-457. PMID: 39558414, PMCID: PMC11798759, DOI: 10.1111/ejh.14337.Peer-Reviewed Original Research
Clinical Care
Overview
Michael Recht, MD, PhD, is a pediatric hematologist who focuses on treating children, adolescents, and young adults with bleeding and clotting disorders.
Dr. Recht is a professor of clinical pediatrics at Yale School of Medicine. He has been actively involved in more than 110 clinical trials, including research on gene therapy for hemophilia. Dr. Recht also serves as the chief medical and scientific officer for the National Bleeding Disorders Foundation. In this role, he helps shape the scientific direction and research strategy of the organization, working to advance the understanding and treatment of bleeding disorders. Dr. Recht received his medical and doctoral degrees from the University of Wisconsin-Madison. He completed his residency in pediatrics and fellowship in pediatric hematology-oncology at Yale New Haven Hospital.
Clinical Specialties
Pediatric Hematology & Oncology
Fact Sheets
Bleeding Disorders
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Appointment Number
Mailing Address
Pediatric Hematology & Oncology
333 Cedar Street
New Haven, CT 06510
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.